| [1] Glezen W P, Taber L H, Frank A L, et al. Risk of primary infection and reinfection with respiratory syncytial virus. American Journal of Diseases of Children (1960),1986,140(6):543-546.
[2] Shay D K, Holman R C, Newman R D, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. Jama,1999,282(15):1440-1446.
[3] Murphy B R, Hall S L, Kulkarni A B, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Research,1994,32(1):13-36.
[4] Wright P F, Karron R A, Belshe R B, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine,2007,25(42):7372-7378.
[5] Wright P F, Karron R A, Belshe R B, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. The Journal of Infectious Diseases,2000,182(5):1331-1342.
[6] Castagne N, Barbier A, Bernard J, et al. Biochemical characterization of the respiratory syncytial virus P-P and P-N protein complexes and localization of the P protein oligomerization domain. The Journal of General Virology,2004,85(Pt 6):1643-1653.
[7] Lu B, Ma C H, Brazas R, et al. The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro. Journal of Virology,2002,76(21):10776-10784.
[8] Sunters A, Fernandez de Mattos S, Stahl M, et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. The Journal of Biological Chemistry,2003,278(50):49795-49805.
[9] Whitehead S S, Firestone C Y, Karron R A, et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increasfes its attenuation and temperature sensitivity. Journal of Virology,1999,73(2):871-877.
[10] Elliott M B, Pryharski K S, Yu Q, et al. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. Journal of Virology,2004,78(16):8446-8454.
[11] Karron R A, Wright P F, Crowe J E, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. The Journal of Infectious Diseases,1997,176(6):1428-1436.
[12] Schmidt U, Beyer J, Polster U, et al. Mucosal immunization with live recombinant bovine respiratory syncytial virus (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV. Journal of Virology,2002,76(23):12355-12359.
[13] Widjojoatmodjo M N, Boes J, van Bers M, et al. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virology Journal,2010,7:114.
[14] Tang R S, Nguyen N, Cheng X, et al. Requirement of cysteines and length of the human respiratory syncytial virus M2-1 protein for protein function and virus viability. Journal of Virology,2001,75(23):11328-11335.
[15] Buchholz U J, Granzow H, Schuldt K, et al. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. Journal of Virology,2000,74(3):1187-1199.
[16] Collins P L, Jr. Crowe J E. Respiratory Syncytial Virus and Metapneumovirus. In:Knipe P M H,Griffin D E, Lamb R A, et al. Fields Virology, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2007: 1601-1646.
[17] Karron R A, Wright P F, Belshe R B, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. The Journal of Infectious Diseases,2005,191(7):1093-1104.
[18] Krempl C, Murphy B R, Collins P L. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. Journal of Virology,2002,76(23):11931-11942.
[19] Biacchesi S, Skiadopoulos M H, Tran K C, et al. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology,2004,321(2):247-259.
[20] Bermingham A, Collins P L. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proceedings of the National Academy of Sciences of the United States of America,1999,96(20):11259-11264.
[21] Buchholz U J, Ward J M, Lamirande E W, et al. Deletion of nonstructural proteins NS1 and NS2 from pneumonia virus of mice attenuates viral replication and reduces pulmonary cytokine expression and disease. Journal of Virology,2009,83(4):1969-1980.
[22] Whitehead S S, Bukreyev A, Teng M N, et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. Journal of Virology,1999,73(4):3438-3442.
[23] Harker J A, Godlee A, Wahlsten J L, et al. Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells. Journal of Virology,2010,84(8):4073-4082.
[24] Bukreyev A, Whitehead S S, Bukreyeva N, et al. Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity. Proceedings of the National Academy of Sciences of the United States of America,1999,96(5):2367-2372.
[25] Harker J A, Lee D C, Yamaguchi Y, et al. Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. Journal of Virology,2010,84(10):5294-5302. |
